We advised Frist Cressey Ventures, which led the round

Davis Polk advised Frist Cressey Ventures in connection with its lead investment in the $20 million Series A preferred stock financing of Aradigm, Inc.

Headquartered in New York, Aradigm, Inc. is a public benefit corporation built to foster sustainable access to transformative cell and gene therapies.

Founded in 2016, Frist Cressey Ventures is a venture capital firm based in Nashville. Frist Cressey focuses on investing in technology and service businesses aiming to improve quality of care, system integration, patient outcomes, and population health and well-being.

The Davis Polk capital markets team included partner Jared Fine and associates Matthew A. Bultman and Jenna Pedrantri. All members of the Davis Polk team are based in the New York office.

Copy link to share post